[{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"CHRO Merger","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pelthos Therapeutics \/ CHRO Merger","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ CHRO Merger"},{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"Channel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pelthos Therapeutics \/ Pelthos Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ Pelthos Therapeutics"},{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"Murchinson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Gel","sponsorNew":"Pelthos Therapeutics \/ Murchinson","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ Murchinson"},{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pelthos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pelthos Therapeutics","sponsor":"Biofrontera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Licensing Agreement","leadProduct":"Ozenoxacin","moa":"DNA gyrase | DNA topoisomerase IV | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Pelthos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Pelthos Therapeutics \/ Pelthos Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Pelthos Therapeutics \/ Pelthos Therapeutics"}]